CHU de Nice - LPCE- Hôpital de Pasteur - 30 ave de la voie Romaine
Nice, Alpes-Maritimes, 06001, France
NCT Number: NCT01776385
Malignant pleural mesothelioma (MPM) has a growing incidence and in spite of early diagnostic, their outcome remains dismal. The evolution of MPM is often local with rare distant metastases. There is now a sizable body of evidence that metastases could develop from circulating tumor cells (CTC) spread in blood before or during surgery. Thus, sensitive and specific detection of CTC in blood is considered as a potentially relevant predictive biomarker for patients with carcinomas. In exchange, the prognostic value of CTC in MPM has not yet been evaluated.
Indeed, the main goal for preoperative detection of CTC is to identify patients with high risk of recurrence after surgery, in order to perform more adapted therapeutic strategy. Despite several studies reported about CTC detection, methodological aspects concerning sensitivity, specificity and reproducibility have prevented a clear appraisal of their clinical impact. Thus, the aim of our study is to evaluate the presence and the prognostic value of CTC in MPM by a double approach. In our setting, cytopathological analysis of circulating non hematological cells (CNHC), of epithelial origin, isolated according to their size (ISET, Isolation by Size of Epithelial Tumor cells) along with immunomagnetic selection, identification and enumeration of circulating epithelial cells in peripheral blood (CellSearch method) is considered a promising approach.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nice, Alpes-Maritimes, 06001, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For the patients:
For the control subjects:
Exclusion criteria
Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
Time frame: from Baseline in Systolic Blood Pressure at 6 months
Value forecasts of the presence / absence of CTC on the global survival estimated by the estimation and the test of meaning at 0 of the immediate relative risk (fate ratio) in a model at proportional risk.
Time frame: from Baseline in Systolic Blood Pressure at 6 months
Value forecasts of the number of CTC on the global survival estimated by the immediate relative risk Value forecasts of the presence / absence and the number of CTC on the survival without second offense(recurrence) or metastasis estimated by the immediate relative risk
Centre Hospitalier Universitaire de Nice
Other
Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04731129
Neoplasms, Neoplasms by Site
Liège, Belgium
View Trial DetailsNCT00591981
Digestive System Diseases, Digestive System Neoplasms
Madison, Wisconsin, United States
View Trial DetailsNCT00087698
Neoplasms, Neoplasms by Site
San Francisco, California, United States
View Trial DetailsNCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial Details